387 related articles for article (PubMed ID: 11331435)
1. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL
Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
[TBL] [Abstract][Full Text] [Related]
2. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Douer D; Hu W; Giralt S; Lill M; DiPersio J
Oncologist; 2003; 8(2):132-40. PubMed ID: 12697938
[TBL] [Abstract][Full Text] [Related]
8. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
[TBL] [Abstract][Full Text] [Related]
9. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Dombret H; Fenaux P; Soignet SL; Tallman MS
Semin Hematol; 2002 Apr; 39(2 Suppl 1):8-13. PubMed ID: 12012316
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
11. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
12. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
15. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
16. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
17. New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Sekeres MA
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365
[TBL] [Abstract][Full Text] [Related]
18. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Sanz MA; Iacoboni G; Montesinos P
Curr Oncol Rep; 2013 Oct; 15(5):445-9. PubMed ID: 23990383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]